Key result
This review appraises available evidence for risk stratification in arrhythmogenic right ventricular cardiomyopathy to guide primary prevention implantable cardioverter-defibrillator therapy.
Why the study?
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy?
Population
Patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC)
Design
Review
Authors
Loading...
Current risk stratification warrants caution for primary prevention ICD decisions in ARVC; leaves open need for validated predictors.
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy?
This review provides evidence-based guidance on risk stratification for sudden cardiac death in ARVC to inform decisions regarding primary prevention ICD therapy.
Cadrin‐Tourigny et al. (2015) conducted a review in Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC). Implantable cardioverter-defibrillator (ICD) therapy and risk stratification was evaluated on Sudden cardiac death. This review appraises available evidence for risk stratification in arrhythmogenic right ventricular cardiomyopathy to guide primary prevention implantable cardioverter-defibrillator therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: